# Predicta Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/predicta-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.predictabiosciences.com
- Total disclosed funding: $29M
- Latest round: Series A (Oct 1, 2025)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2023 by CEO Irene Ghobrial, CTO Ken Anderson, and co-founder Gad Getz, Predicta Biosciences, Inc., operates as a healthtech company providing precision oncology for businesses that uses multiomics to create cutting-edge medical and diagnostic tools. In October 2025, Predicta Biosciences, Inc. raised USD 23.4 million in series A funding led by returning investor Engine Ventures, with participation from new investors Lightchain Capital, Mass General Brigham Ventures, BrightEdge Ventures, Binney Street Capital, and Myeloma Investment Fund. Other unspecified and another returning investor Illumina Ventures also participated in the round.

Predicta Biosciences, Inc. developed precision oncology for transforming diagnostic and therapeutic tools for the patients. The company offers diagnostic products that eliminates invasive bone-marrow biopsies, instead utilizing small blood-based samples. The Predicta platform captures multi-omics and immune system data to build a clinical database. In addition, the firm provides artificial intelligence-based tools that mines the data to discover novel therapeutic targets and immune signatures.

The company will use the October 2025 funding to expand its AI-driven drug discovery platform and grow its team.

## Funding rounds

- Series A, Oct 1, 2025, $23M — Mass General Brigham Ventures, Illumina Ventures, Engine Ventures, BrightEdge Ventures, Lightchain Capital, Binney Street Capital, Myeloma Investment Fund
- Seed, Jul 16, 2024, $5.2M — Illumina Ventures, Engine Ventures, American Cancer Society

## Investors

- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Seed, Series A
- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Seed, Series A
- American Cancer Society — Seed
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series A
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series A
- Binney Street Capital (https://capitalatlas.ai/funds/binney-street-capital) — Series A
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series A